Short courses of zidovudine and perinatal transmission of HIV. 1999

P Thomas, and K Bornschlegel

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011251 Pregnancy Complications, Infectious The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION. Complications, Infectious Pregnancy,Infectious Pregnancy Complications,Maternal Sepsis,Pregnancy, Infectious Complications,Sepsis during Pregnancy,Sepsis in Pregnancy,Infectious Pregnancy Complication,Pregnancy Complication, Infectious,Sepsis in Pregnancies,Sepsis, Maternal
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018445 Infectious Disease Transmission, Vertical The transmission of infectious disease or pathogens from one generation to another. It includes transmission in utero or intrapartum by exposure to blood and secretions, and postpartum exposure via breastfeeding. Fetomaternal Infection Transmission,Infection Transmission, Fetomaternal,Infection Transmission, Maternal-Fetal,Infection Transmission, Vertical,Maternal-Fetal Infection Transmission,Mother-to-Child Transmission,Pathogen Transmission, Vertical,Vertical Infection Transmission,Vertical Infectious Disease Transmission,Vertical Transmission of Infectious Disease,Infection Transmission, Maternal Fetal,Maternal Fetal Infection Transmission,Mother to Child Transmission,Mother-to-Child Transmissions,Transmission, Fetomaternal Infection,Transmission, Maternal-Fetal Infection,Transmission, Mother-to-Child,Transmission, Vertical Infection,Transmission, Vertical Pathogen,Transmissions, Mother-to-Child,Vertical Pathogen Transmission
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

P Thomas, and K Bornschlegel
April 1999, The New England journal of medicine,
P Thomas, and K Bornschlegel
April 1999, The New England journal of medicine,
P Thomas, and K Bornschlegel
April 1999, The New England journal of medicine,
P Thomas, and K Bornschlegel
September 1995, American family physician,
P Thomas, and K Bornschlegel
November 1999, Acta paediatrica (Oslo, Norway : 1992),
P Thomas, and K Bornschlegel
January 1997, American family physician,
P Thomas, and K Bornschlegel
April 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
P Thomas, and K Bornschlegel
November 1998, The New England journal of medicine,
P Thomas, and K Bornschlegel
February 1998, BMJ (Clinical research ed.),
Copied contents to your clipboard!